Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,239,455 papers from all fields of science
Search
Sign In
Create Free Account
APF530
Known as:
APF-530
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
I. Schnadig
,
R. Agajanian
,
+10 authors
J. Vacirca
Future oncology
2016
Corpus ID: 207343574
AIM APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy…
Expand
2016
2016
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly…
R. Boccia
,
E. O’Boyle
,
W. Cooper
BMC Cancer
2016
Corpus ID: 2609853
BackgroundAPF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h…
Expand
2015
2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
H. Raftopoulos
,
R. Boccia
,
W. Cooper
,
E. O’Boyle
,
R. Gralla
Future oncology
2015
Corpus ID: 43347834
BACKGROUND APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to…
Expand
2015
2015
Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
R. Boccia
,
W. Cooper
,
E. O’Boyle
The Journal of community and supportive oncology
2015
Corpus ID: 45021457
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained…
Expand
2015
2015
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
N. Gabrail
,
R. Yanagihara
,
+4 authors
R. Boccia
Cancer management and research
2015
Corpus ID: 21777990
Background Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy…
Expand
2014
2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly…
H. Raftopoulos
,
W. Cooper
,
E. O’Boyle
,
N. Gabrail
,
R. Boccia
,
R. Gralla
Supportive Care in Cancer
2014
Corpus ID: 15305333
PurposeSubcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h…
Expand
2014
2014
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
T. Ottoboni
,
M. Gelder
,
E. O’Boyle
Journal of experimental pharmacology
2014
Corpus ID: 16215708
Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy…
Expand
2014
2014
A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation
J. Mason
,
T. Moon
,
E. O’Boyle
,
A. Dietz
Cancer management and research
2014
Corpus ID: 17272372
Background Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted…
Expand
2013
2013
Sustainability of antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens: Results of a…
R. Boccia
,
W. Cooper
,
E. O’Boyle
2013
Corpus ID: 79819695
9626 Background: Patients receiving MEC or HEC were administered subcutaneous (SC) APF530 500 mg, a sustained delivery…
Expand
2009
2009
Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).
J. Grous
,
E. Riegel
,
+8 authors
J. Barr
Journal of clinical oncology : official journal…
2009
Corpus ID: 21071829
9627 Background: APF530 is a polymeric formulation of granisetron providing sustained drug release over 5 days. Two doses (5 and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE